Cara Therapeutics Q4 2022 revenue $3.3M, net loss $30.3M; FY22 revenue $41.9M

Tvardi Therapeutics, Inc.

Q4 2022 total revenue $3.3M (incl. $1.1M collaborative revenue from KORSUVA profit share); FY22 total revenue $41.9M.
Q4 2022 net loss $30.3M ($0.56 per share); FY22 net loss $85.5M ($1.59 per share).
Cash and equivalents $156.7M at Dec 31, 2022; expects to fund operations into first half of 2024.
KORSUVA injection net sales $2.3M in Q4, $35.3M for FY22; wholesaler shipments 20,844 vials in Q4, 207,096 for FY22.
Phase 2/3 program of oral difelikefalin for NP initiated; PMDA decision in Japan expected H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tvardi Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 6, 2023, Cara Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-029006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.